SCHEMBL5207812

SCHEMBL5207812

CC1CCc2nc(N)sc2C1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.62
DRD3 P35462 5/20 0.55
DRD2 P14416 4/20 0.55
HRH2 P25021 2/20 0.55
ADRA2A P08913 2/20 0.55
DRD4 P21917 2/20 0.55
ADRB2 P07550 1/20 0.55
HTR1A P08908 1/20 0.55
ADRA2B P18089 1/20 0.55
ADRA2C P18825 1/20 0.55
HTR1B P28222 1/20 0.55
HTR2A P28223 1/20 0.55
HTR7 P34969 1/20 0.55
ADRA1A P35348 1/20 0.55
HRH1 P35367 1/20 0.55
HTR2B P41595 1/20 0.55
SIGMAR1 Q99720 1/20 0.55
HRH4 Q9H3N8 1/20 0.55
MAPT P10636 4/20 0.54
LMNA P02545 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204000 0.85 APOBEC3A (0.48) PDK1DRD3DRD2HRH2ADRA2A
SCHEMBL2051128 0.79 LMNA (0.55) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL306889 0.79 LMNA (0.55) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL10264578 0.79 PDK1 (0.64) PDK1MAPTLMNAHSD17B10GAA
SCHEMBL306888 0.79 LMNA (0.55) DRD3DRD2HRH2ADRA2ADRD4
Hydrochloric Acid SCHEMBL942873 0.78 LMNA (0.54) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL8209089 0.78 LMNA (0.54) DRD3DRD2HRH2ADRA2ADRD4
SCHEMBL6865505 0.78 LMNA (0.54) DRD3DRD2HRH2ADRA2ADRD4
Bromide SCHEMBL1193429 0.78 LMNA (0.54) DRD3DRD2HRH2ADRA2ADRD4
Hydrochloric Acid SCHEMBL1032722 0.78 LMNA (0.54) DRD3DRD2HRH2ADRA2ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115976584-B Copper electroplating solution suitable for filling ultra-deep hole TSV and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2025-01-28 CN claimed
CN-115976584-A Copper electroplating solution suitable for filling ultra-deep hole TSV and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2023-04-18 CN claimed
CN-115976584-B Copper electroplating solution suitable for filling ultra-deep hole TSV and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2025-01-28 CN disclosed
CN-115976584-B Copper electroplating solution suitable for filling ultra-deep hole TSV and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2025-01-28 CN disclosed
US-20240409533-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-12-12 US disclosed
CN-113874074-B HMOX1 inducers 米托布里奇公司 2024-11-01 CN disclosed
US-12071433-B2 HMOX1 inducers Astellas Engineered Small Molecules US, Incorporated (US) 2024-08-27 US disclosed
US-20240051952-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-02-15 US disclosed
CN-115976584-A Copper electroplating solution suitable for filling ultra-deep hole TSV and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2023-04-18 CN disclosed
CN-115976584-A Copper electroplating solution suitable for filling ultra-deep hole TSV and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2023-04-18 CN disclosed
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors Nanjing Immunophage Biotech Co., Ltd. (CN) 2023-02-09 US disclosed
US-20130079323-A1 GYRASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2013-03-28 US disclosed
EP-2548877-A1 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors MSD Oss B.V. (NL) 2013-01-23 EP disclosed
US-20110190356-A1 Compositions and Methods of Using (R)- Pramipexole KNOPP NEUROSCIENCES INC. (US) 2011-08-04 US disclosed
US-7868029-B2 Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles from cyclohexanes and cyclohexanones as intermediates GENERICS [UK] LIMITED (GB) 2011-01-11 US disclosed
EP-1343561-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
EP-1343561-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-09-17 EP disclosed
WO-2003048155-A1 THROMBIN INHIBITORS UNIVERSITY OF LJUBLJANA (SI) 2003-06-12 WO disclosed
WO-2002047762-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2002-06-20 WO disclosed
US-4321372-A Antiulcer thiazol-2-ylcarbamoyl-carboxylic acids, esters and amides PFIZER INC. (US) 1982-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079323-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B PDK1 3170/4885DRD3 3169/4885DRD2 4210/4885
US-20240409533-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS PDK1 2257/4885DRD3 3047/4885DRD2 3598/4885
US-12071433-B2 HMOX1 inducers HMOX1, HMOX2, HMBS PDK1 1876/4885DRD3 3565/4885DRD2 3953/4885
US-20240051952-A1 HMOX1 INDUCERS HMOX1, HMOX2, QSOX1 PDK1 2672/4885DRD3 3045/4885DRD2 3677/4885
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors CCR8, CCR1, CCR3 PDK1 4218/4885DRD3 3789/4885DRD2 4540/4885
US-20110190356-A1 Compositions and Methods of Using (R)- Pramipexole HSPE1, GRIN2B, GRIN2A PDK1 260/4885DRD3 2284/4885DRD2 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.